Development of Flightless antibody therapy for treating wounds

开发用于治疗伤口的Flightless抗体疗法

• 批准号: nhmrc : 508006
• 负责人: Prof Allison Cowin
• 金额: $ 12.94万
• 依托单位: The University of Adelaide
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-flightless-antibody-treating-wounds/99746
• 关键词: Development; Flightless; antibody; therapy; treating

Chronic wounds, diabetic ulcers, injuries in response to trauma, burns and scalds form a medical need which will only expand as the population ages and the diabetic epidemic grows. In our studies, we have shown that Flightless I (FliI), an actin-remodelling protein, is a negative regulator of incisional wound healing. We are now developing a new antibody therapy to reduce FliI levels in wounds thereby leading to improved wound repair outcomes.

慢性伤口、糖尿病溃疡、创伤、烧伤和烫伤引起的伤害形成了医疗需求，随着人口老龄化和糖尿病流行病的增长，这种需求只会扩大。在我们的研究中，我们已经表明，Flightless I（FliI），一种肌动蛋白重塑蛋白，是切口伤口愈合的负调节因子。我们现在正在开发一种新的抗体疗法，以降低伤口中的FliI水平，从而改善伤口修复结果。